Navigation Links
EGEN, Inc. Announces the Promotion of Khursheed Anwer, Ph.D., to President and Chief Scientific Officer
Date:6/3/2009

ositions since 2002, most recently as Senior Vice-President and Chief Scientific Officer. In these positions he has led the execution of EGEN's proprietary discovery and development initiatives leading to EGEN's strong intellectual property position, was instrumental in building EGEN's research and development team and fostered important industry collaborations that are underway.

"I am pleased to have the opportunity to continue my personal contributions to EGEN's success," said Dr. Anwer. "I look forward to working with the Board of Directors and moving EGEN's technology forward to create additional value for our shareholders. We are poised to take the company's novel technology to the next level and make the promise of nucleic acid (DNA, RNAi) therapeutics become a reality."

About EGEN, Inc.

EGEN, Inc., is a privately held biopharmaceutical company located in Huntsville, Alabama and is focused on developing therapeutics for the treatment of human diseases via nucleic acid (DNA and RNAi) delivery. The Company has a significant intellectual property position in delivery systems, their novel compositions with nucleic acids and their therapeutic applications. EGEN's research pipeline includes products involving siRNA, shRNA and plasmid DNA for the treatment of various cancers and other diseases and has a number of collaborations with outside investigators, biotech organizations and universities on various projects in these areas.

For more information on EGEN, please visit http://www.egeninc.com/ .


'/>"/>
SOURCE EGEN, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
2. Amylin Announces Preliminary Tabulation of Annual Meeting Results
3. Cynosure Announces Presentations at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
5. Assay Designs(TM), Inc. Announces Release of First Available Product for Multiplex Analysis of Heat Shock Proteins
6. Valeritas Announces Appointment of New CEO
7. Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
8. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
9. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
10. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. TorreyPines Therapeutics Announces its Board of Directors Approval of Plan of Liquidation and Dissolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 ... technologies such as the Bioruptor® and complete solutions ... system for chromatin immunoprecipitation, alleviating the need for ... and controls needed for ChIP of histones or ...
(Date:1/22/2015)...   GenoSpace , a precision medicine software company that has ... use of genomic, imaging and other biomedical data in research ... Munson , CEO of Aspera, an IBM Company, to its ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to welcome ...
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Bulletin Board: ACCP) announced today that it will make ... Conference to be held,November 10-12, 2008 at the New ... scheduled to speak on Tuesday, November 11, 2008 at ... and discuss the Company,s,product opportunities., The presentation will ...
... ROCKVILLE, Md., Nov. 6 EntreMed, Inc.,(Nasdaq: ... the treatment of cancer and inflammatory diseases, today,reported ... September 30,2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ), ... approximately $3,501,000,versus $3,520,000 for the comparable period a ...
... safety profile of Ranexa -, - Conference ... -, PALO ALTO, Calif., Nov. 6 ... that the U.S. Food and Drug,Administration (FDA) has ... extended-release tablets) for the treatment of,chronic angina. The ...
Cached Biology Technology:Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference 2EntreMed Reports Third Quarter 2008 Financial Results 2EntreMed Reports Third Quarter 2008 Financial Results 3EntreMed Reports Third Quarter 2008 Financial Results 4EntreMed Reports Third Quarter 2008 Financial Results 5FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 2FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 3FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 4FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 5
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today announced the ... ancestry of individuals from across the United States ... four hundred years ago, the United States ... different continents. This study illuminates how American history and the ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced today its ... confirm its adherence to current U.S. Food and Drug ... regulated smart device and smart phone application trials utilizing ... "HITLAB is determined to improve global healthcare ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Infectious Diseases (NIAID), part of the National Institutes ... $80 million for two new Regional Centers of ... (RCE). The grants to the University of California, ... the completion of a national network of academic ...
... with implications for pandemic influenza, a new study reports for ... virus can spread from poultry to humans. The research ... Infectious Diseases, now available online. , Crossing the species barrier ... virus with pandemic potential. Previous studies have focused on the ...
... problem of "super-bugs" - bacteria that have become resistant ... high rate of antibiotic prescribing in hospitals contributes to ... antibiotics, an even more important factor contributing to such ... access international medical journal PLoS Medicine, is the use ...
Cached Biology News:New NIAID grants strengthen national biodefense and emerging infectious diseases research network 2Less virulent strains of avian influenza can infect humans 2Agricultural antibiotic use contributes to 'super-bugs' in humans 2
... 400 unique human proteins on a ... proteins, a cross section of all ... for high-quality results. Additional control proteins ... high validity and reproducibility., ,UNIchip protein ...
...
... The benchmark for analytical performance ... ease-of-use and the ultimate in ... Varian 810-MS features include: ... optics minimize,interferences, providing reliable, routine, ...
... it uses a deep-UV deuterium bulb, which provides ... a shutter (controlled via a TTL signal or ... DH-2000 Deuterium Tungsten Halogen Light Source combines the ... sources in a single optical path. The combined-spectrum ...
Biology Products: